65 Group Management Work Experience Dr Prem Kumar Nair was appointed Group Chief Executive Officer of IHH Healthcare on 1 October 2023, where he leads a team of more than 70,000 employees to realise IHH’s vision to be the world’s most trusted healthcare services network. Dr Nair sets the strategic direction for the sustainable growth of IHH’s global network which today comprises more than 80 hospitals in 10 countries. Guided by its Care. For Good. aspiration, Dr Nair continues to build on the IHH portfolio of strong and reputable brands including Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai, Parkway and Island - to touch lives and transform care globally. Before his role as Group CEO, he served as CEO of IHH Singapore since 2020, where he oversaw the country’s business units and played a pivotal role in strategic growth and international outreach. Prior to that, Dr Nair was with Raffles Medical Group for 27 years, where he held concurrent roles as Chief Corporate Officer, and Managing Director for Singapore Healthcare. With over three decades of experience as a physician and healthcare executive in both public and private sectors, Dr Nair has earned accolades such as Wellbeing CEO at the WorkWell Leaders Award 2024 and Asia’s Best CEO at the Corporate Governance Asia - Asian Excellence Award 2024. An active community citizen in Singapore, Dr. Nair was a recipient of the Public Service Medal (Pingat Bakti Masyarakat) in 2010 and, at the 2022 National Day Awards, he received both the Public Service Star (Bintang Bakti Masyarakat) and the Public Service Medal (PBM COVID-19), respectively, for his contributions to the Singapore Prison Service and his support of national COVID-19 efforts. He is also a Justice of the Peace and an Adjunct Associate Professor at the National University of Singapore’s Saw Swee Hock School of Public Health. Academic/Professional Qualification(s) • Bachelor of Medicine & Surgery, National University of Singapore • Master of Business Administration (Distinction), Manchester Business School, United Kingdom Work Experience A seasoned finance and general management executive with over 27 years of leadership experience across investment banking, healthcare, and multinational corporations, Mr Dilip Kadambi currently serves as the Group Chief Financial Officer of IHH Healthcare. In this role, he leads the group’s financial strategy and management, overseeing corporate finance, treasury, financial planning and analysis, investor relations, tax, procurement, and IT functions globally. Mr Dilip joined IHH in 2020 as the Group Head of Business Transformation before expanding his role to include Corporate Finance and Treasury. Prior to his current position, he also led the Group Procurement function, driving cost optimisation and operational efficiencies. Before joining IHH, Mr Dilip served as the Interim Group Chief Executive Officer and Group Chief Financial Officer at Columbia Asia Healthcare from 2015 to 2020, overseeing finance and operations. His career also includes senior leadership roles at Standard Chartered Bank, CIMB Bank Berhad, the Royal Bank of Scotland, and ABN AMRO Bank across Singapore and India, specialising in corporate finance, M&A advisory, and investment banking. Mr Dilip’s expertise spans financial restructuring, treasury management, capital markets, investor relations, and corporate transformation. He has a proven track record of leading complex financial transactions and delivering shareholder value. Academic/Professional Qualification(s) • Post Graduate Diploma in Business Administration, Institute of Chartered Financial Analyst • Bachelor of Commerce, Madras University, India Dilip Kadambi Group Chief Financial Officer Nationality: Indian Gender: Male Age: 50 (As at 1 April 2025) Date of Appointment: 5 April 2024 Dr Prem Kumar Nair Group Chief Executive Officer Nationality: Singaporean Gender: Male Age: 64 (As at 1 April 2025) Date of Appointment: 1 October 2023 Notes • Does not have any family relationships with any directors and/or major shareholders of the Company. • Dr Prem Kumar Nair has less than 5% equity interest in a fund that has invested in Leo Cancer Care. During the financial year, Dr Prem Kumar Nair had declared his potential conflict of interest (COI) in respect of IHH’s participation in research consortium for upright radiotherapy formed by Leo Cancer Care. To ensure that all potential COI issues are properly addressed, he had not been involved/shall not be involved in such transaction in any manner at all times and shall abstain from all deliberations, discussions, and votings, where relevant, on IHH’s investment decision in Leo Cancer Care at IHH level. • Dilip Kadambi does not have any conflict of interest with the Company. • Does not have any convictions for offences within the past five years other than for traffic offences, if any.
RkJQdWJsaXNoZXIy NDgzMzc=